NCT03814447

✓ Unanimous Initial: outpatient

✓ Unanimous Initial: inpatient Requery: inpatient — CAR-T cell therapy involves intensive conditioning chemotherapy (cyclophosphamide and fludarabine) followed by cell infusion and monitoring for serious adverse events including cytokine release syndrome, which requires hospitalization and continuous medical supervision. Thinking: outpatient — The trial protocol does not explicitly state that patients are admitted or hospitalized during CAR-T cell therapy administration.

✓ Unanimous Initial: outpatient Requery: outpatient — The intervention involves administering a dose of CAR-T cells without indication of hospitalization, consistent with outpatient clinical trial practices. Thinking: outpatient — The protocol does not state that participants are admitted for the intervention, so by default the CAR-T infusion and follow-up are assumed to be delivered to ambulatory patients.

✓ Unanimous Initial: no Requery: no — The intervention consists of a single pharmacologic/biological treatment protocol where lymphodepletion chemotherapy (fludarabine and cyclophosphamide) is used merely as a preparatory regimen to support the primary CAR-T cell therapy.

✓ Unanimous Initial: yes Requery: no — This is a single-modality cell therapy intervention where the preparative chemotherapy (fludarabine and cyclophosphamide) serves as standard conditioning for CAR-T cell infusion rather than representing separate therapeutic components.

✓ Unanimous Initial: no Requery: no — The intervention involves a single type of approach, CAR-T cell therapy, combined with preparatory chemotherapy, which does not qualify as multi-component from different categories.